



THANK YOU FOR YOUR CONTINUED LOYALTY TO

THE SANOFI PASTEUR INFLUENZA VACCINE PORTFOLIO

2021-2022 SEASON

WE LOOK FORWARD TO AN ONGOING COMMITMENT TOWARD SIMPLIFYING YOUR VACCINE CHOICES FOR PERSONS 6 MONTHS OF AGE AND OLDER

	Packaging	Syringes and Vials	Ages ¹⁻³	Presentation ¹⁻³	Dosing Schedule ¹⁻⁴	CPT ^a Codes and Coverage ⁵	NDC ^b Information ⁶		EMR ^c Code
							Package NDC	Unit NDC	
			65 years of age and older	0.7-mL single-dose prefilled syringe	1 dose	90662 Covered by most health plans and Medicare Part B	49281-0121-65	49281-0121-88	
			18 years of age and older	0.5-mL single-dose prefilled syringe	1 dose	90682 Covered by most health plans and Medicare Part B	49281-0721-10	49281-0721-88	
			6 months of age and older	0.5-mL single-dose prefilled syringe	1 or 2 doses Per Advisory Committee on Immunization Practices (ACIP) guidance, children 6 months through 8 years of age require 2 doses of influenza vaccine (given at least 4 weeks apart) in the flu season, if they are considered inadequately primed.	90686 Covered by most health plans and Medicare Part B	49281-0421-50 0.5-mL single-dose prefilled syringe	49281-0421-88 0.5-mL single-dose prefilled syringe	
				0.5-mL single-dose vial		90685 (0.25-mL dose) Covered by most health plans and Medicare Part B	49281-0421-10 0.5-mL single-dose vial	49281-0421-58 0.5-mL single-dose vial	
				5-mL multidose vial		90687 (0.25-mL dose) 90688 (0.5-mL dose) Covered by most health plans and Medicare Part B	49281-0635-15 5-mL multidose vial	49281-0635-78 5-mL multidose vial	

^a CPT (Current Procedural Terminology) is a registered trademark of the American Medical Association. ^b NDC = National Drug Code. ^c EMR = Electronic medical record.

Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent are vaccines **indicated** for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Fluzone Quadrivalent is approved for use in persons 6 months of age and older. Flublok Quadrivalent is approved for use in persons 18 years of age and older. Fluzone High-Dose Quadrivalent is approved for use in persons 65 years of age and older.

IMPORTANT SAFETY INFORMATION

Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent should not be administered to anyone who has had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine (including egg protein for Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent) or after previous dose of the respective vaccine. In addition, Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent should not be administered to anyone who has had a severe allergic reaction after previous dose of any influenza vaccine.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent should be based on careful consideration of the potential benefits and risks.

If Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent are administered to immunocompromised persons, including those receiving immunosuppressive therapy, the immune response may be lower than expected.

Vaccination with Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent may not protect all recipients.

For Fluzone Quadrivalent, in children 6 months through 35 months of age, the most common injection-site reactions were pain or tenderness, erythema, and swelling; the most common solicited systemic adverse reactions were irritability, abnormal crying, malaise, drowsiness, appetite loss, myalgia, vomiting, and fever. In children 3 years through 8 years of age, the most common injection-site reactions were pain, erythema, and swelling; the most common solicited systemic adverse reactions were myalgia, malaise, and headache. In adults 18 years and older, the most common injection-site reaction was pain; the most common solicited systemic adverse reactions were myalgia, headache, and malaise.

For Flublok Quadrivalent, in adults 18 through 49 years of age, the most common injection-site reactions were tenderness and pain; the most common solicited systemic adverse reactions were headache, fatigue, myalgia, and arthralgia. In adults 50 years of age and older, the most common injection-site reactions were tenderness and pain; the most common solicited systemic adverse reactions were headache, and fatigue.

For Fluzone High-Dose Quadrivalent, in adults 65 years of age and older, the most common injection-site reaction was pain; the most common solicited systemic adverse reactions were myalgia, headache, and malaise.

For Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent, other adverse reactions may occur.

Before administration, please see accompanying full Prescribing Information for [Fluzone Quadrivalent](#), [Flublok Quadrivalent](#), or [Fluzone High-Dose Quadrivalent](#).

References: **1.** Fluzone High-Dose Quadrivalent [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc. **2.** Flublok Quadrivalent [Prescribing Information]. Meriden, CT: Protein Sciences Corporation. **3.** Fluzone Quadrivalent [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc. **4.** Centers for Disease Control and Prevention (CDC), Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2020–21 influenza season. *MMWR Recomm Rep.* 2020;69(8):1–24. **5.** Centers for Medicare and Medicaid Services. Seasonal influenza vaccines pricing. <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/VaccinesPricing>. Accessed August 14, 2020. **6.** Sanofi Pasteur Inc. Data on file (2021-2022 Influenza Vaccine Availability; Sanofi Pasteur).